Myasthenia Gravis in the Setting of Immune Checkpoint Inhibitor Therapy: Practical Considerations and Opinion-Based Approach to Acute Management. | Cureus;14(10): e30638, 2022 Oct. | MEDLINE

Main content 1 Search 2 Footer 3

+A A -A High contrast

VHL Regional Portal

Information and Knowledge for Health

Advanced Search EVID@Easy

Myasthenia Gravis in the Setting of Immune Checkpoint Inhibitor Therapy: Practical Considerations and Opinion-Based Approach to Acute Management.

Zubair, Adeel S; Roy, Bhaskar; Baehring, Joachim M; Nowak, Richard J.

Affiliation

Zubair AS; Neurology, Yale School of Medicine, New Haven, USA.
Roy B; Neurology, Yale School of Medicine, New Haven, USA.
Baehring JM; Neurology, Yale School of Medicine, New Haven, USA.
Nowak RJ; Neurology, Yale School of Medicine, New Haven, USA.

Cureus ; 14(10): e30638, 2022 Oct.

Article in En | MEDLINE | ID: mdl-36439604

Key words

anti-ctla4; anti-pd1; anti-pdl1; checkpoint inhibitor; myasthenia gravis

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Cureus Year: 2022 Document type: Article Affiliation country: Country of publication:

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Prognostic_studies Language: En Journal: Cureus Year: 2022 Document type: Article Affiliation country: Country of publication: